P840: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF PEGCETACOPLAN USING PRINCE TRIAL DATA VERSUS RAVULIZUMAB AND ECULIZUMAB IN COMPLEMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

• R. Wong,
• J. Fishman,
• K. Wilson,
• M. Yeh,
• Z. Hakimi,
• C. Yee,
• L. Huynh,
• M. S. Duh

Affiliations

R. Wong

1 Sir Y.K. Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong

J. Fishman

2 Apellis Pharmaceuticals, Waltham, United States of America

K. Wilson

3 Swedish Orphan Biovitrum AB, Stockholm, Sweden

M. Yeh

2 Apellis Pharmaceuticals, Waltham, United States of America

Z. Hakimi

3 Swedish Orphan Biovitrum AB, Stockholm, Sweden

C. Yee

4 Analysis Group, Boston, United States of America

L. Huynh

4 Analysis Group, Boston, United States of America

M. S. Duh

4 Analysis Group, Boston, United States of America